Viramatix is focused on developing peptide-based therapeutics to address significant unmet medical needs in viral infections, particularly influenza, cytomegalovirus (CMV), respiratory syncytial virus (RSV), herpes simplex virus (HSV), and HIV. Their innovative approach involves the identification of peptide compounds that demonstrate high potency against a wide range of influenza viruses, including both seasonal and pandemic strains, as well as non-human variants. The company has conducted extensive in vitro and in vivo testing to confirm the efficacy of these compounds, which have shown minimal toxicity in various human and animal cell types. Their mechanism of action primarily involves binding to the matrix protein of the influenza virus, effectively preventing the emergence of drug-resistant strains.

In addition to their work on influenza, Viramatix has made significant progress in developing therapeutics for other viral infections. They have identified promising leads that inhibit the replication of CMV, RSV, and HSV-2, which are currently undergoing testing in animal models and toxicology studies. For HIV, the company is optimizing novel peptides to enhance their efficacy against different subtypes while minimizing toxicity. This comprehensive pipeline reflects Viramatix's commitment to addressing the challenges posed by viral diseases and their potential to provide effective treatment options where current therapies fall short.

Malaysia

Viramatix Ltd is a discovery stage bio-pharmaceutical company, involved in the development of peptide based therapeutics against infectious diseases of unmet medical need. We seek to innovate in the areas of anti-viral, anti-bacterial and anti-fungal therapeutics development.

Viramatix

Company Details